Data Presented at ATTD 2017 Demonstrate Clinical Advantages of Tandem Diabetes Care Sensor-augmented Pump (SAP) over Medtroni...
February 15 2017 - 1:00PM
Business Wire
– Additional Presentation of Self-reported Data
Demonstrates Reduced Risk of Hypoglycemia with Tandem Pumps
Compared to Previous Therapy –
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device
company and manufacturer of the only touchscreen insulin pumps
available in the United States, today presented study results
comparing retrospective user data from sensor-augmented pumps
(SAPs) made by Tandem Diabetes Care and Medtronic Minimed®. SAPs
receive continuous glucose monitoring (CGM) data from a wearable
sensor. The Tandem SAP demonstrated statistically significant
clinical advantages, including reduced hypoglycemia, increased time
in range, and improved overall glycemic control, despite
approximately half of Medtronic SAP users actively using a feature
that suspends insulin delivery if blood glucose falls below a
preset threshold. These data were presented during a poster session
at the 10th Annual Advanced Technologies and Treatments for
Diabetes (ATTD) International Conference in Paris, France.
“This study suggests that our simple-to-use touchscreen
interface may translate to improved clinical outcomes for people
with diabetes," said Betsy Dokken, PhD, Director of Clinical
Affairs at Tandem Diabetes Care. "The data reinforces our assertion
that not every insulin pump delivers the same benefits, and that
choice in therapy options is important for the diabetes
community.”
A retrospective study was conducted in which de-identified
Tandem SAP user data from the period of October 2015 – August 2016
were collected from the t:connect® Diabetes Management Application
for analysis (n=3,046). These findings were compared to similar
data collected from the CareLink® Therapy Management System between
September 2011 and October 2013.1 Both the Tandem and the Medtronic
data sets utilized the same inclusion criteria: people with type 1
and type 2 diabetes using a SAP, at least 6 months of sensor use,
and more than 15 days of CGM use during the first 6 months.
Compared with Medtronic SAP user results, those using the Tandem
SAP demonstrated:
- Reduced
Hypoglycemia - Tandem SAP users showed reduced time in each
of the hypoglycemic ranges. The effect size is large and persists
regardless of the frequency of sensor usage.
- Increased Time in
Range - Tandem SAP users who utilized the sensor at least
25% of the time showed increased time in range relative to
Medtronic SAP users with the same sensor usage time.
- Improved Overall
Glycemic Control - The Tandem SAP demonstrated improved
control across all glycemic ranges for subjects using the sensor at
least 75% of the time. These users spent less time both
hypoglycemic and hyperglycemic when compared to users of the
Medtronic SAPs.
Based on earlier data demonstrating a greater ease-of-use and
lower rate of error for the t:slim® Insulin Pump2, the current
results may be related to the usability benefits introduced by the
touchscreen, suggesting that the intuitive user interface of the
Tandem SAP translates into better outcomes in everyday life.
In a second poster presentation, data were presented from a
study demonstrating a reduced risk of hypoglycemia associated with
Tandem pump use compared to previous methods of diabetes therapy.
Data were collected from patients with either type 1 (90%) or type
2 (10%) diabetes who had been using a Tandem pump for at least 1
year (N = 1,370). Participants voluntarily filled out an online
survey with questions about the occurrence of mild hypoglycemic
events (able to treat the low themselves), medium hypoglycemic
events (needed assistance from someone but did not need to go to
the hospital) and severe hypoglycemic events (needed assistance
from a medical professional and/or needed to go the hospital).
Questions focused on both the year before starting a Tandem pump
(using previous method of diabetes therapy) and the past year using
their Tandem pump. Results demonstrated that, even when controlling
for CGM usage, Tandem pump users reported a 52% reduction in severe
hypoglycemia, a 31% reduction in medium hypoglycemia, and a 15%
reduction in mild hypoglycemia, compared to previous methods of
diabetes therapy. Furthermore, there was a statistically
significant reduction in ambulance rides due to severe hypoglycemia
of 58% and in days spent at the hospital due to severe hypoglycemia
of 50%.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company with an innovative, user-centric and integrated
approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest
and smallest durable insulin pump currently on the market, the
t:flex® Insulin Pump, the first pump designed for people with
greater insulin requirements, and the t:slim G4™ Insulin Pump, the
first continuous glucose monitoring-enabled pump with touchscreen
simplicity. Tandem is based in San Diego, California.
Any forward-looking statements are subject to risks and
uncertainties including those identified in the Company’s most
recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q, as well as other documents that the Company files with the
Securities and Exchange Commission. Actual results may differ
materially from those anticipated or projected in this release.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use
#tslimX2, #tslimG4, #tflex, #tconnect, and $TNDM.Follow Tandem
Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.Follow
Tandem Diabetes Care on LinkedIn at
https://www.linkedin.com/company/tandemdiabetes.t:slim, t:flex and
Tandem Diabetes Care are registered trademarks, and t:slim X2 and
t:slim G4 are trademarks of Tandem Diabetes Care, Inc. Medtronic,
Minimed and Carelink are registered trademarks of Medtronic,
Inc.
1 Battelino T, Liabat S, Veeze HJ, Castañeda J, Arrieta A, Cohen
O. Routine use of continuous glucose monitoring in 10 501 people
with diabetes mellitus. Diabet Med. 2015;32:1568–1574.2 Schaeffer,
N. E., Parks, L. J., Verhoef, E. T., et al. Usability and training
differences between two personal insulin pumps. J Diabetes Sci
Technol, March 2015 vol. 9 no. 2 221-230.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170215005304/en/
Tandem Diabetes Care, Inc.Media Contact:Steve
Sabicer, 714-907-6264ssabicer@thesabicergroup.comorInvestor
Contact:Susan Morrison, 858-366-6900
x7005smorrison@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Sep 2023 to Sep 2024